Deals channel feed

Failed PhI­I­Is af­ter a re­jec­tion by the FDA spur Sanofi to dump its $1.7B deal with Lex­i­con on di­a­betes drug — shares crash

6 years ago
R&D

Boston's Neu­roBo to use bruised Gem­phire to make Nas­daq de­but

6 years ago

A 2-year-old fledg­ling biotech steers in­to PhI­II and nabs a quick $565M buy­out deal

6 years ago

As Take­da ab­sorbs Shire’s R&D ops, the fo­cus is on re­plac­ing a cen­tral­ized com­mand mod­el with a ‘light touch’ in a re­struc­tured glob­al or­ga­ni­za­tion

6 years ago
R&D

Cel­gene re­struc­tures a big Jounce pact, ze­ro­ing in on new I/O path­way with $530M deal — and bump­ing ICOS

6 years ago

Roche cuts loose Tam­i­flu OTC rights, hand­ing Sanofi the keys as the phar­ma gi­ant dou­bles down on Xofluza

6 years ago
Pharma

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

6 years ago

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

6 years ago
Pharma

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

6 years ago

Cu­ri­ous case of stock price moves re­veals Sum­it­o­mo Dainip­pon is eye­ing $202M buy­out of Aus­tralian stem cell play­er

6 years ago

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

6 years ago

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

6 years ago

Take­da preps an­oth­er drug auc­tion as ex­ecs look to fur­ther trim its post-Shire buy­out debt load — re­port

6 years ago
Pharma

Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

6 years ago

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

6 years ago

Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

6 years ago

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

6 years ago
Discovery

Deal hun­gry So­sei Hep­tares brings Roche's Genen­tech on board as a part­ner

6 years ago

Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

6 years ago

Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

6 years ago

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
R&D
Pharma

KRAS G12C is the hot new play in can­cer R&D, and No­var­tis jumps in with a com­bo deal

6 years ago
R&D

Cel­gene turns to Nim­bus on ‘high­ly prized’ I/O tar­get — land­ing right in Bris­tol-My­ers’ sweet spot

6 years ago

More de­lays? Now Roche’s CEO says he’s will­ing to wait well in­to next year to com­plete their $4.3B Spark buy­out

6 years ago
First page Previous page 101102103104105106107 Next page Last page
A service from the Financial Times